Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer - PubMed
5 hours ago
- #non-small cell lung cancer
- #genomic profiling
- #personalized medicine
- The Lung-ONE study assessed the utility of comprehensive genomic profiling (CGP) tests like FoundationOne in guiding second-line therapy for advanced NSCLC patients in Spain.
- FMI tests identified 542 driver mutations in actionable genes across 132 patients, including previously missed mutations in EGFR, ALK, and BRAF, and additional alterations in ERBB2/HER2, MET, and RET.
- Clinicians used FMI data to modify treatment decisions, directing 29.1% of patients toward off-label drugs and 8.6% toward clinical trials, demonstrating its benefit over standard-of-care single-gene testing.